Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Wednesday.

Several other analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. initiated coverage on Karyopharm Therapeutics in a research note on Wednesday, November 15th. They set a “buy” rating and a $23.00 target price for the company. Royal Bank Of Canada restated a “buy” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Robert W. Baird restated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $17.33.

Shares of Karyopharm Therapeutics (KPTI) traded down $0.33 during trading hours on Wednesday, reaching $10.33. The company had a trading volume of 89,791 shares, compared to its average volume of 235,037. Karyopharm Therapeutics has a 1 year low of $7.48 and a 1 year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities analysts forecast that Karyopharm Therapeutics will post -2.59 earnings per share for the current year.

In other Karyopharm Therapeutics news, SVP Christopher Brett Primiano sold 4,958 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total value of $55,777.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the sale, the director now owns 2,882 shares of the company’s stock, valued at approximately $31,702. The disclosure for this sale can be found here. Insiders sold a total of 13,458 shares of company stock valued at $152,778 in the last quarter. Corporate insiders own 14.71% of the company’s stock.

Several hedge funds have recently made changes to their positions in KPTI. Vanguard Group Inc. lifted its position in shares of Karyopharm Therapeutics by 31.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after acquiring an additional 384,658 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Karyopharm Therapeutics by 753.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after buying an additional 271,208 shares in the last quarter. Tekla Capital Management LLC raised its holdings in shares of Karyopharm Therapeutics by 25.0% in the 2nd quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock worth $6,848,000 after buying an additional 151,455 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Karyopharm Therapeutics by 36.5% in the 2nd quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock worth $3,668,000 after buying an additional 108,369 shares in the last quarter. Finally, Iguana Healthcare Management LLC raised its holdings in shares of Karyopharm Therapeutics by 33.3% in the 3rd quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock worth $4,392,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 60.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics (KPTI) Rating Lowered to Strong Sell at ValuEngine” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/06/karyopharm-therapeutics-kpti-rating-lowered-to-strong-sell-at-valuengine.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.